Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

October 25, 2023

Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for Camrelizumab + Rivoceranib for uHCC

October 25, 2023

Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA

October 25, 2023

Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

October 18, 2023

MediLink Therapeutics Announces Strategic Collaboration And Worldwide License Agreement With BioNTech To Develop Next-Gen Anti-Cancer ADCs

October 18, 2023

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

October 18, 2023

Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Gen Radioligand Therapies

October 11, 2023

Bristol Myers Squibb to acquire Mirati Therapeutics

October 11, 2023

BriaCell Partners with NYCBS for Pivotal Ph3 Study of Bria-IMT in Advanced Breast Cancer

October 11, 2023

Ankyra Therapeutics and Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

October 11, 2023

Nektar Therapeutics and Cellular Biomedicine Group to Evaluate NKTR-255 + C-TIL051 in Advanced NSCLC

October 3, 2023

AbbVie terminated agreement with Caribou Biosciences regarding development of next-generation, off-the-shelf CAR-T cell therapies

October 3, 2023

AbbVie is terminating its agreement with I-Mab to develop certain CD47 antibody compounds, including the programme’s lead drug lemzoparlimab

October 3, 2023

BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®

September 26, 2023

1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA

September 26, 2023

Collaborative Trial to Study PP2A Inhibitor, LB-100, Plus Dostarlimab, in Clear-Cell Ovarian Cancer announced

September 26, 2023

Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Taiho Oncology to Evaluate LYTGOBI + BBI-355 in Patients with FGFR Amplified Solid Tumors

September 26, 2023

Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Lilly to Evaluate VERZENIO + BBI-355 in Patients with CDK4/6 Amplified Solid Tumors

September 26, 2023

Roche partners with PeptiDream on peptide-radioisotope drug conjugates

September 26, 2023

Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers

September 26, 2023

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091

September 19, 2023

Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

September 19, 2023

Nurix Announces Strategic Collaboration with Seagen Combining Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance a New Class of Cancer Therapeutics

September 19, 2023

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

September 19, 2023

AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology

September 19, 2023
Page1 … Page16 Page17 Page18 Page19 Page20 … Page26

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.